Trial Profile
A Retrospective Study of Immunotherapy in Elderly Population
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Jun 2018
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 05 Jun 2018 New trial record